BeiGeneius Hematology Summit – Relapsed/refractory CLL and indolent lymphomas
A multidisciplinary panel review the latest developments in R/R CLL and indolent lymphomas and share expert overviews of clinical trial interpretation and best practice in patient communication.
Recent advances in R/R CLL

Clinical scenarios in R/R CLL

Recent advances in R/R indolent lymphomas

Audience-directed discussion: Future challenges in indolent lymphomas

Debate: Bispecific antibodies are a better therapeutic option than CAR-T therapies for early relapsing FL

How to interpret a trial: Design and statistics

Improving communication between hematologists and patients: Talking about risk, uncertainty, and clinical trials
